Granted Patent
B2
US 9,090,597 · App. 14/473,338 · Granted Jul 28, 2015
Pyrazolone derivatives as PDE4 inhibitors
Inventors:
Beate Schmidt (Allensbach, DE); Christian Scheufler (Engen-Heuhausen, DE); Jürgen Volz (Radolfzell, DE); Martin Feth (Kelkheim-Hornau, DE); Rolf-Peter Hummel (Radolfzell, DE); Armin Hatzelmann (Constance, DE); Christof Zitt (Constance, DE); Andrea Wohlsen (Neuchatel, CH); Degenhard Marx (Moos, DE); Hans-Peter Kley (Allensbach, DE); Deborah Ockert (Hamburg, DE); Anke Heuser (Hamburg, DE); Johannes A. M. Christiaans (DG Lelystad, NL); Geert Jan Sterk (JJ Utrecht, NL); Wiro M. P. B. Menge (HM Arnhem, NL)
Assignee:
Takeda GmbH
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione is a novel effective inhibitor of the type 4 phosphodiesterase useful in the treatment of psoriasis or atopic dermatitis.
Claims (3)
1. A method for treating psoriasis or atopic dermatitis in a patient comprising administering to a patient in need thereof the compound 1-(2-{4-[3-(3,4-dimethoxyphenyl)-4,4-dimethyl-5-oxo-4,5-dihydro-1H-pyrazol-1-yl]piperidin-1-yl}-2-oxoethyl)pyrrolidine-2,5-dione.
2. The method according to claim 1 , wherein the disease to be treated is psoriasis.
3. The method according to claim 1 , wherein the disease to be treated is atopic dermatitis.
Assignments (3)
CHANGE OF NAME
Recorded Jul 29, 2015
From: NYCOMED GERMANY HOLDING GMBH
To: TAKEDA GMBH
Reel/Frame 036205/0179 →
MERGER
Recorded Jul 28, 2015
From: TAKEDA GMBH
To: NYCOMED ASSET MANAGEMENT GMBH
Reel/Frame 036193/0224 →
MERGER
Recorded Jul 28, 2015
From: NYCOMED ASSET MANAGEMENT GMBH
To: NYCOMED GERMANY HOLDING GMBH
Reel/Frame 036201/0478 →
Priority Claims (1)
EP 07108314
· May 16, 2007
· regional
Continuity (3)
Continuation
12451348